EUVAX B

This brand name is authorized in Brazil, Ecuador, Malta, Poland, Romania, Tunisia, Turkey, South Africa

Active ingredients

The drug EUVAX B contains one active pharmaceutical ingredient (API):

1 Hepatitis B, purified antigen UNII IFJ010MNE4 - HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer. Read about Hepatitis B, purified antigen

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BC01	Hepatitis B, purified antigen	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BC Hepatitis vaccines
Discover more medicines within J07BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 576720060071517, 576720060071617, 576720060071717, 576720060071817, 576720060071917
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 20.248-1-03-03
Country: MT	Medicines Authority	Identifier(s): AA729/16203
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100030713, 100098190
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W60084001, W60084002, W60085001, W60085002, W60085003
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 12303011, 12303012
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699686961044, 8699686961051
Country: ZA	Health Products Regulatory Authority	Identifier(s): 35/30.1/0024